Paolo A. Ascierto

Research interests

Publications

• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407417

• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  Zurich Open Repository and Archive (University of Zurich) · 2022 · https://doi.org/10.5167/uzh-213514

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002435

• Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)30934-x

• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910836

• Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.02105

• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.04.001

• International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

  The Lancet · 2018 · 10.1016/s0140-6736(18)30789-x

• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1802357

• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30142-6

• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1709030

• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709684

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1611299

• Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30122-x

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30098-5

• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504030

• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00083-2

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70076-8

• Nivolumab in Previously Untreated Melanoma without BRAF Mutation

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1412082

• Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1408868

• Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70012-9

• Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

  The Journal of Pathology · 2013 · 10.1002/path.4287

• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70431-x

• The role of BRAF V600 mutation in melanoma

  Journal of Translational Medicine · 2012 · 10.1186/1479-5876-10-85

• Cancer classification using the Immunoscore: a worldwide task force

  Journal of Translational Medicine · 2012 · 10.1186/1479-5876-10-205

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782

Current projects

No projects listed.